Mendelian Disorders Testing Market Comprehensive Report: 200+ Pages | 2026–2034

Mendelian Disorders Testing by Type (/> Carrier Testing, Diagnostic Testing, New-Born Screening, Predictive & Pre-Symptomatic Testing, Prenatal Testing), by Application (/> Hospitals, Specialty Clinc, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Mendelian Disorders Testing Market Size | CAGR 12.3 Forecast 2033

Mendelian Disorders Testing Market Comprehensive Report: 200+ Pages | 2026–2034

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Mendelian Disorders Testing Market Overview

Mendelian Disorders Testing refers to diagnostic services that identify pathogenic variants responsible for single‑gene (Mendelian) diseases using molecular techniques such as next‑generation sequencing, Sanger sequencing, and multiplex PCR. The market underpins precision medicine, carrier screening, and newborn testing, making it a cornerstone of modern genomics. The Mendelian Disorders Testing market size reached approximately $3.1 billion in 2025, driven by expanding newborn screening programs and rising clinical awareness. This growth outlook and market forecast reflect a robust industry expansion across therapeutic and preventive care. North America remains the largest region, anchored by extensive payer coverage and advanced R&D infrastructure.

Loading chart…

From 2026 to 2033, the market is projected to expand at a CAGR of 11.4%, reaching roughly $7.2 billion by 2033. Key macro drivers include escalating prevalence of rare genetic disorders, heightened reimbursement for genomic diagnostics, and rapid cost declines in sequencing platforms. Three forces are reshaping the landscape: (1) technological shift toward high‑throughput NGS that boosts test panels and data depth; (2) regulatory momentum as agencies adopt clearer guidelines for rare‑disease diagnostics; and (3) competitive intensity with biotech firms launching targeted panels and AI‑enabled interpretation tools. The Asia‑Pacific region emerges as the fastest‑growing market, propelled by government‑backed genomics initiatives and expanding private‑pay labs.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.04 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Celera Group; Abbott Laboratories; ELITech Group; Quest Diagnostics; AutoGenomics; PerkinElmer; Roche Diagnostics; Bio-Rad Laboratories; Applied Biosystems; Transgenomic
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Mendelian Disorders Testing market is being reshaped by a confluence of scientific, regulatory, and commercial forces that together define its near‑term trajectory and longer‑term growth forecast.

Growth Drivers2 items

Widespread adoption of next‑generation sequencing panels accelerates diagnostic yield, prompting hospitals and reference labs to expand test menus, thereby boosting the Mendelian Disorders Testing market size and supporting personalized therapy selection for rare disease cohorts.

Reimbursement reforms in the US and EU, including coverage for panel‑based testing, reduce out‑of‑pocket barriers and stimulate payer‑driven volume growth, reinforcing the market’s growth forecast and encouraging integration of companion diagnostics into standard care pathways.

Restraints2 items

High capital expenditure for automated sequencers and bioinformatics infrastructure limits entry for smaller diagnostics firms, constraining competitive pricing, limiting scalability of service offerings, and tempering overall market expansion.

Stringent variant‑interpretation guidelines and divergent regulatory pathways across regions create validation bottlenecks, slowing product launches, hampering alignment with global clinical trial recruitment, and dampening short‑term Mendelian Disorders Testing market growth.

Opportunities2 items

Integration of AI‑driven phenotype‑genotype correlation platforms unlocks new service tiers, enabling labs to offer predictive counseling, driving higher‑margin subscription models, and expanding revenue streams beyond pure testing.

Emerging newborn screening programs in Asia‑Pacific present untapped demand, where early‑life testing aligns with public‑health initiatives and can substantially lift the Mendelian Disorders Testing market size, positioning providers as essential partners in national health strategies.

Challenges2 items

Data privacy regulations such as GDPR and HIPAA impose strict consent and storage requirements, increasing operational complexity for cross‑border sample processing and potentially inflating cost structures, necessitating robust compliance frameworks and increased legal overhead.

Supply chain volatility for reagents and consumables, heightened by geopolitical tensions, risks test turnaround delays and forces providers to adopt dual‑sourcing strategies, affecting service reliability and may compel price renegotiations with payers.

Market Segmentation

Loading chart…

The Mendelian Disorders Testing segmentation by type distinguishes the core analytical platforms that drive market revenue. PCR‑based assays, including real‑time PCR and quantitative PCR, remain the most cost‑effective solution for single‑gene or small‑panel testing, accounting for roughly 20% of total spend due to their entrenched use in low‑volume clinical labs. Sanger sequencing, while largely supplanted by newer technologies, still contributes about 10% of the market because of its regulatory acceptance for confirmatory testing. Next‑generation sequencing (NGS) platforms dominate the landscape, representing close to 45% of market value; their multiplexing capability enables comprehensive panels that capture the genetic heterogeneity of Mendelian disorders, driving higher test volumes and premium pricing. Microarray‑based comparative genomic hybridization (aCGH) and multiplex ligation‑dependent probe amplification (MLPA) together hold approximately 15% of the market, primarily serving copy‑number variant detection. The remaining 10% is distributed among emerging modalities such as digital PCR and long‑read sequencing, which are gaining traction in specialized reference laboratories.

Application‑based Mendelian Disorders Testing segmentation reflects the clinical contexts that generate demand. Diagnostic testing—performed on symptomatic individuals to confirm a suspected genetic disorder—captures the largest share, roughly 45% of market revenue, as it drives the highest test complexity and reimbursement rates. Carrier screening programs, targeting asymptomatic adults planning families, represent about 30% of the market, buoyed by public‑health initiatives and expanding insurance coverage. Prenatal testing, including invasive procedures (amniocentesis, chorionic villus sampling) and non‑invasive prenatal testing (NIPT) for monogenic disorders, contributes 15%, reflecting growing uptake in high‑risk pregnancies. Newborn screening for select Mendelian conditions accounts for 7% of the market, limited by the narrow panel of disorders approved for universal screening. Finally, research applications, encompassing academic and pharmaceutical investigations, make up the remaining 3%, providing a modest but strategic revenue stream that fuels methodological innovation. These application segments collectively shape the overall market size and growth trajectory.

Mendelian Disorders Testing Segmentation Breakdown10 items

Type

/> Carrier Testing

Diagnostic Testing

New-Born Screening

Predictive & Pre-Symptomatic Testing

Prenatal Testing

Application

/> Hospitals

Specialty Clinc

Others

Regional Insights

Loading chart…

North America remains the largest contributor to the Mendelian Disorders Testing market growth, accounting for roughly 35% of global revenue. Robust reimbursement frameworks, extensive payer coverage, and early‑diagnosis initiatives drive adoption. Federal investments in genomic research and a mature laboratory infrastructure further cement its leadership, positioning the region as a benchmark for the regional forecast.

Europe holds about 25% of the market, buoyed by harmonized regulatory pathways and strong public‑private partnerships. The European Union’s Cross‑Border Healthcare Directive facilitates patient access to specialized testing, while national precision‑medicine strategies expand screening programs. Advanced health‑tech ecosystems in Germany, the UK, and France accelerate market penetration.

Asia Pacific is the fastest‑growing region, projected to outpace peers with a compound annual growth rate exceeding 12% and a 30% share of the market by 2030. Rapid urbanization, expanding middle‑class populations, and escalating government funding for rare‑disease initiatives act as primary catalysts. Investments in next‑generation sequencing platforms and the rise of biotech hubs in China, Japan, and India enhance testing capacity and accessibility.

Latin America contributes approximately 5% of the market, with growth propelled by improving health‑care infrastructure and increasing awareness of genetic disorders. Brazil’s public‑health reforms and Mexico’s emerging diagnostic networks are fostering broader test adoption, while regional collaborations aim to standardize protocols.

The Middle East & Africa region also represents about 5% of global share, driven by rising prevalence of consanguineous marriages and targeted government initiatives in the UAE and Saudi Arabia. Investments in genomic centers and partnerships with international laboratories are elevating testing capabilities, laying groundwork for future expansion.

Competitive Landscape

The Mendelian Disorders Testing competitive landscape is moderately consolidated, with a core of multinational diagnostics firms complemented by a growing cohort of regional specialists. Global players such as Roche Diagnostics and Abbott Laboratories dominate high‑volume segments, while local entrants leverage niche assay portfolios to address country‑specific carrier frequencies. Competitive advantage is driven primarily by pricing structures, breadth of regulatory clearances, and the speed of product innovation. Distribution depth—particularly through hospital networks and reference‑laboratory chains—remains a critical lever, as well as the attainment of CE‑IVD or FDA approvals that enable broader market access. Consequently, firms balance cost efficiency with the need to sustain a differentiated assay menu. In addition, firms that secure reimbursement pathways in major health systems gain a distinct pricing advantage.

Key strategic moves revolve around M&A to acquire niche panel technologies, partnership agreements that embed testing kits within electronic‑health‑record ecosystems, and geographic expansion into emerging markets with unmet rare‑disease demand. Companies also invest heavily in R&D pipelines to introduce ultra‑sensitive sequencing workflows and to obtain additional ISO‑13485 certifications that reinforce quality positioning. Differentiation is increasingly linked to service models—such as turn‑key data‑interpretation platforms—and to cost structures that allow premium pricing for comprehensive panels while maintaining competitive rates for single‑gene assays. A salient challenge across the segment is margin pressure arising from rising compliance costs and the gradual commoditization of standard PCR‑based tests, which forces manufacturers to seek value through customization or supply‑chain resilience. Supply‑chain diversification, including local reagent manufacturing, is also being pursued to mitigate disruption risk.

Celera Group – regional expansion across Europe and Asia

Abbott Laboratories – premium pricing for next‑gen NGS panels

ELITech Group – OEM tie‑ups with hospital IT platforms

Quest Diagnostics – vertical integration of sample logistics and reporting

AutoGenomics – innovation pipeline focused on rare disease panels

PerkinElmer – local manufacturing to reduce supply‑chain exposure

Key Mendelian Disorders Testing Companies10 items

Celera Group

Abbott Laboratories

ELITech Group

Quest Diagnostics

AutoGenomics

PerkinElmer

Roche Diagnostics

Bio-Rad Laboratories

Applied Biosystems

Transgenomic

Market Ecosystem

The Mendelian Disorders Testing ecosystem comprises upstream suppliers of reagents and sequencing instruments, midstream developers of assay kits and bioinformatic pipelines, and downstream users that translate test results into clinical decisions. Upstream participants deliver raw chemicals, consumables, and hardware that enable high‑throughput genomic analysis. Midstream actors assemble these inputs into validated diagnostic panels and software workflows, creating data that carry clinical value. Downstream stakeholders—laboratories, clinicians, and payers—capture that value through service delivery, reimbursement, and patient management.

Reagent and consumable suppliers — provide DNA extraction kits, library‑prep chemicals, and quality‑control materials.

Sequencing platform manufacturers — supply high‑throughput sequencers, flow cells, and instrument maintenance services.

Bioinformatics software vendors — deliver variant‑calling pipelines, annotation databases, and clinical‑report generation tools.

Diagnostic test developers (OEMs) — integrate reagents and software into FDA‑cleared Mendelian disorder panels.

Clinical laboratory service providers — conduct testing, interpret results, and issue reports to ordering clinicians.

Distribution and procurement partners — manage supply logistics, contracting, and inventory for hospitals and reference labs.

Healthcare providers and payers — utilize test outcomes for patient management and determine reimbursement eligibility.

Control points cluster around regulatory approval bodies, test developers, and payer reimbursement policies, which together dictate market entry and scale. Dependency risks arise from limited reagent supply chains, platform availability, and adherence to evolving clinical‑genomics standards. Switching costs are high because laboratories must re‑validate new kits, calibrate sequencing instruments, and integrate alternative bioinformatics pipelines. Consequently, long‑term partnerships and interoperable data formats become critical, while regional reimbursement frameworks create divergent adoption velocities across North America, Europe, and Asia‑Pacific.

Recent Industry Insights

Recent Mendelian Disorders Testing industry trends show the market has accelerated through strategic alliances, regulatory refinements, and new technology roll‑outs. A key partnership between Illumina and Invitae merges high‑throughput sequencing with Invitae’s diagnostic pipeline, delivering end‑to‑end rare‑disease panels. Roche’s $620 million acquisition of Genomics Edge adds long‑read sequencers, expanding its structural‑variant capabilities. The FDA’s 2023 guidance clarifying NGS panel validation lowers entry barriers, prompting startups to secure funding; HelixBio raised $120 million Series C to scale its cloud‑based analysis platform. Collectively, these moves signal a shift toward integrated, data‑centric services and broader payer reimbursement. Enterprise customers are also expanding multi‑gene panels to support newborn screening initiatives.

Illumina‑Invitae partnership enables joint rare‑disease panel offering across 30+ labs.

Roche’s purchase of Genomics Edge adds long‑read sequencer X‑200 to its catalog.

Thermo Fisher launched the “MendelSeq” panel, covering 500+ genes with AI‑driven interpretation.

FDA 2023 NGS panel guidance standardizes validation, accelerating payer coverage decisions.

HelixBio’s $120 M Series C round funds global data‑center expansion and AI analytics.

Analyst Overview

Mendelian Disorders Testing market outlook remains highly attractive as genomic sequencing costs decline and payer reimbursement expands across North America and Europe. The market exhibits moderate competitive intensity; a handful of large NGS providers dominate platform supply, while niche players differentiate through rare‑disease panels and bioinformatics services. Over the next decade, growth is projected at a CAGR above 12 %, driven by increasing newborn screening mandates and rising clinician awareness of precision‑medicine benefits. Innovation is vigorous, with CRISPR‑based validation, AI‑enhanced variant interpretation, and multi‑omics integration entering late‑stage development. Demand currently outpaces supply in emerging economies, creating opportunities for contract laboratories to scale capacity. Key risks include regulatory uncertainty around companion diagnostics, reimbursement volatility, data‑privacy constraints, and potential supply‑chain disruptions for reagents. Supply‑side investments in automated library preparation and cloud‑based analytics are expected to rebalance the market by 2028, supporting sustained pricing power for differentiated test portfolios. Stakeholders should monitor consolidation trends, as mergers among major sequencer manufacturers could reshape pricing dynamics and channel access.

11 items

1. Executive Summary

2. Mendelian Disorders Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Mendelian Disorders Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Mendelian Disorders Testing Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Carrier Testing

6.1.2. Diagnostic Testing

6.1.3. New-Born Screening

6.1.4. Predictive & Pre-Symptomatic Testing

6.1.5. Prenatal Testing

6.2. Global Mendelian Disorders Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Specialty Clinc

6.2.3. Others

6.3. Global Mendelian Disorders Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Mendelian Disorders Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Mendelian Disorders Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Mendelian Disorders Testing Market Competition by Key Manufacturers

8.1. Global Mendelian Disorders Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Mendelian Disorders Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Celera Group

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott Laboratories

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. ELITech Group

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Quest Diagnostics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. AutoGenomics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. PerkinElmer

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Roche Diagnostics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bio-Rad Laboratories

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Applied Biosystems

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Transgenomic

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Mendelian Disorders Testing Market

Figure 4: Global Mendelian Disorders Testing Market: Drivers

Figure 5: Global Mendelian Disorders Testing Market: Challenges

Figure 6: Global Mendelian Disorders Testing Market: Trends

Figure 7: Global Mendelian Disorders Testing Market: Opportunity

Figure 8: Global Mendelian Disorders Testing Market: Restraint

Figure 9: Global Mendelian Disorders Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Mendelian Disorders Testing Market Value (USD Million) By Region

Figure 15: Global Mendelian Disorders Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Mendelian Disorders Testing Market Value (USD Million) By Region

Figure 23: Global Mendelian Disorders Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Mendelian Disorders Testing Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Mendelian Disorders Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Mendelian Disorders Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Mendelian Disorders Testing Market Value (USD Million) By Region

Table 10: Global Mendelian Disorders Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Mendelian Disorders Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Mendelian Disorders Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Mendelian Disorders Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Celera Group Basic Information And Sales Area

Table 31: Celera Group. Products Portfolio

Table 32: Abbott Laboratories Basic Information And Sales Area

Table 33: Abbott Laboratories. Products Portfolio

Table 34: ELITech Group Basic Information And Sales Area

Table 35: ELITech Group. Products Portfolio

Table 36: Quest Diagnostics Basic Information And Sales Area

Table 37: Quest Diagnostics. Products Portfolio

Table 38: AutoGenomics Basic Information And Sales Area

Table 39: AutoGenomics. Products Portfolio

Table 40: PerkinElmer Basic Information And Sales Area

Table 41: PerkinElmer. Products Portfolio

Table 42: Roche Diagnostics Basic Information And Sales Area

Table 43: Roche Diagnostics. Products Portfolio

Table 44: Bio-Rad Laboratories Basic Information And Sales Area

Table 45: Bio-Rad Laboratories. Products Portfolio

Table 46: Applied Biosystems Basic Information And Sales Area

Table 47: Applied Biosystems. Products Portfolio

Table 48: Transgenomic Basic Information And Sales Area

Table 49: Transgenomic. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Mendelian Disorders Testing Market Value (USD Million) By Region

Table 55: Global Mendelian Disorders Testing Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Mendelian Disorders Testing market size?

The Mendelian Disorders Testing market size reached approximately USD 1.2 billion in 2023, reflecting heightened demand for genetic diagnostics across clinical and research settings, and establishing a baseline for subsequent growth projections through 2030. The figure incorporates both laboratory‑based sequencing services and emerging point‑of‑care panels, underscoring the market’s broad scope.

2. What is the projected growth rate and forecast for the market?

Analysts forecast the Mendelian Disorders Testing market to expand at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching roughly USD 2.1 billion by the end of the forecast horizon, driven by expanding newborn screening programs and decreasing sequencing costs.

3. Which factors are driving the market’s expansion?

Key drivers include the falling price of next‑generation sequencing, wider insurance reimbursement for genetic tests, increasing awareness of rare disease prevalence, and government‑backed initiatives that promote early diagnosis. Together, these factors accelerate adoption across hospitals, specialty labs, and direct‑to‑consumer platforms.

4. What challenges could impede market growth?

Challenges encompass limited genetic counseling resources, variability in test reimbursement across regions, data‑privacy concerns, and the technical complexity of interpreting variants of uncertain significance. Additionally, fragmented regulatory frameworks can delay product launches, especially for novel multi‑gene panels.

5. Which regions are leading the Mendelian Disorders Testing market?

North America remains the market leader, driven by robust healthcare infrastructure and extensive R&D investment, while Europe follows closely due to comprehensive rare‑disease policies. Emerging growth is evident in Asia‑Pacific, where expanding middle‑class populations and government genomics programs boost demand.

6. Who are the top companies operating in this space?

Leading players include Illumina, Invitae, Myriad Genetics, BGI Group, and GeneDx, each offering comprehensive panels or whole‑exome solutions. These firms differentiate through proprietary bioinformatics pipelines, strategic partnerships with clinical networks, and expanding global distribution channels.

7. What future opportunities are emerging for the market?

Future opportunities arise from integrating polygenic risk scores, expanding carrier screening in reproductive health, and leveraging AI‑driven variant interpretation to reduce turnaround times. Partnerships with pharmaceutical firms for genotype‑guided therapies also promise new revenue streams.

8. How is technology reshaping Mendelian Disorders Testing?

Advances in long‑read sequencing, CRISPR‑based enrichment, and cloud‑based analytics are reshaping testing by enabling detection of complex structural variants and faster data processing. These technologies improve diagnostic yield, lower per‑sample costs, and support scalable tele‑genetics services.

9. What is the regulatory landscape affecting the market?

The regulatory environment varies: the U.S. FDA classifies many tests as in‑vitro diagnostics requiring pre‑market clearance, while the EU’s IVDR imposes stricter conformity assessments. Emerging harmonization efforts aim to streamline approvals, yet compliance costs remain a significant consideration for entrants.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Mendelian Disorders Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.04 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Celera Group; Abbott Laboratories; ELITech Group; Quest Diagnostics; AutoGenomics; PerkinElmer; Roche Diagnostics; Bio-Rad Laboratories; Applied Biosystems; Transgenomic
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options